Aeterna Zentaris Inc.
|Number of Estimates|
Aeterna Zentaris Inc. is a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests. The Company's lead product, macimorelin, is the first and only U.S. FDA and European Commission approved oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). Macimorelin is currently marketed in the United States under the tradename Macrilen™through a license agreement with Novo Nordisk where Aeterna Zentaris receives royalties on sales. According to a commercialization and supply agreement, MegaPharm Ltd. will seek regulatory approval and then commercialize macimorelin in Israel and the Palestinian Authority. Additionally, upon receipt of pricing and reimbursement approvals, Aeterna expects that macimorelin will be marketed in Europe and the United Kingdom through a recently established license agreement with Consilient Health Ltd and Aeterna Zentaris will receive royalties on sales and other potential payments.
Market Cap: 64.5 Million
Primary Exchange: NASDAQ CAPITAL MARKET
Shares Outstanding: 74 Million
Dividend: 0.0 (0.0%)
Industry: Biological Product (except Diagnostic) Manufacturing
Longest drawdown: 2164 trading days
From: 2013-01-29 To: 2021-05-17
Microcaps mostly among midday movers
via: SeekingAlpha at 2019-06-13 08:41:38:000
Gainers: Coda Octopus Group (NASDAQ: CODA ) +40% . Mmtec (NASDAQ: MTC ) +30% . Red Robin Gourmet Burgers (NASDAQ: RRGB ) +29% . DryShips (NASDAQ: DRYS ) +24% . Cemtrex (NASDAQ: CETX ) +21% . Ruhnn Holding Limited (NASDAQ: RUHN ) +21% . RH (NYSE: RH ) +20% . Aeterna Zentaris (N… read more...
|Ex-Date||Payment Date||Record Date||Declared Date||Amount||Flag||Dividend Type||Qualified||Indicated|
|Ex-Date||Declared Date||Record Date||Payment Date||Ratio||To Factor||For Factor|